Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Diabetes News

Category: Medication


Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure

April 11th 2022

We provided the first evidence that CD34+ HSPC express GLP-1R and that LIRA can favorably impact on cell dysfunction due to HG exposure. These findings open new perspectives on the favorable CV effects of GLP-1 RAs in T2DM patients (Cardiovascular Diabetology)

Categories: Cardiovascular, Medication, News
Tags: liraglutide, stem cells

Categories: Cardiovascular, Medication
Tags: liraglutide, stem cells

Efficacy of liraglutide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials

April 8th 2022

Liraglutide reduced the levels of Blood Glucose, BMI, renal outcome indicators, and serum inflammatory factors of patients with T2DN, suggesting the beneficial effects of liraglutide on renal function (BMC Endocrine Disorders)

Categories: Medication, Nephropathy, News
Tags: liraglutide

Categories: Medication, Nephropathy
Tags: liraglutide

Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study

April 6th 2022

A prespecified sensitivity analysis of protocol-compliant participants showed a significant difference in HbA1c concentration between groups. No new safety signals were identified and there was a low risk of severe hypoglycaemia (The Lancet Diabetes & Endocrinology)

Categories: Medication, News, Paediatrics
Tags: dapagliflozin, HbA1c, Type 2 Diabetes

Categories: Medication, Paediatrics
Tags: dapagliflozin, HbA1c, Type 2 Diabetes

Effects of Pentoxifylline on Serum Markers of Diabetic Nephropathy in Type 2 Diabetes

April 6th 2022

Add-on pentoxifylline to losartan may have more effective anti-inflammatory and anti-albuminuric roles and therefore may be more applicable in the management of diabetic nephropathy compared with high-dose losartan alone (Diabetes Therapy)

Categories: Medication, Nephropathy, News
Tags: pentoxifylline, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: pentoxifylline, Type 2 Diabetes

Efficacy and safety of oral semaglutide by subgroups of patient characteristics in the PIONEER phase 3 programme

April 5th 2022

Oral semaglutide demonstrated consistently greater HbA1c and body weight reductions across a range of patient characteristics, with greater HbA1c reductions seen at higher baseline HbA1c levels (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: HbA1c, PIONEER, semaglutide

Categories: Medication
Tags: HbA1c, PIONEER, semaglutide

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases

March 30th 2022

This systematic review and meta-analysis of RCTs found that use of GLP-1 RAs was associated with increased risk of gallbladder or biliary diseases, especially when used at higher doses, for longer durations, and for weight loss (JAMA Internal Medicine)

Categories: Medication, News, Pathology
Tags: gallbladder, GLP-1 RA

Categories: Medication, Pathology
Tags: gallbladder, GLP-1 RA

Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently

March 30th 2022

Increasing evidence suggests that sodium–glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes (Diabetes Therapy)

Categories: Medication, News
Tags: SGLT2 inhibitors

Categories: Medication
Tags: SGLT2 inhibitors

Beyond the Glycaemic Control of Dapagliflozin: Microangiopathy and Non-classical Complications

March 26th 2022

Dapagliflozin contributes to the control of CV risk factors and reduces the risk of microvascular complications (nephropathy and retinopathy) and other non-classical complications of T2DM. The underuse of SGLT2i in general and dapagliflozin in particular, even in patients whose profiles suggest that they could greatly benefit from SGLT2i treatment, indicates that greater effort is needed to translate scientific evidence into actual clinical practice to improve patients’ quality of life (Diabetes Therapy )

Categories: Medication, News
Tags: dapagliflozin, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication
Tags: dapagliflozin, SGLT2 inhibitors, Type 2 Diabetes

Renoprotective effect of additional sodium-glucose cotransporter 2 inhibitor therapy in type 2 diabetes patients with rapid decline and preserved renal function

March 25th 2022

Early intervention with SGLT2i may have renoprotective effects in T2D patients with rapid decline and preserved renal function (Journal of Diabetes Investigation)

Categories: Medication, Nephropathy, News
Tags: renoprotective, SGLT2 inhibitors, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: renoprotective, SGLT2 inhibitors, Type 2 Diabetes

Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD

March 24th 2022

In patients with T2D treated with simvastatin, fenofibrate reduced the composite of HF hospitalizations or cardiovascular mortality, an effect that was seen predominantly in patients with standard background glucose-lowering therapy (Diabetes Care)

Categories: Medication, News, Treatment
Tags: fenofibrate, simvastatin, Type 2 Diabetes

Categories: Medication, Treatment
Tags: fenofibrate, simvastatin, Type 2 Diabetes

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes

March 20th 2022

These studies have established finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, as an effective treatment for kidney and CV protection and welcomed addition to the pillars of treatment to slow CKD progression in patients with T2D (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: finerenone, Type 2 Diabetes

Categories: Cardiovascular, Medication, Nephropathy
Tags: finerenone, Type 2 Diabetes

Automated Insulin Delivery with SGLT2i Combination Therapy in Type 1 Diabetes

March 14th 2022

In an 8-week outpatient study, addition of 5 mg daily empagliflozin to commercially available AID or PLGS systems significantly improved daytime glucose control in individuals with T1D, without increased hypoglycemia risk. However, the risk of ketosis and ketoacidosis remains (Diabetes Technology and Therapeutics)

Categories: Medication, News, Treatment
Tags: Empagliflozin

Categories: Medication, Treatment
Tags: Empagliflozin

Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials

March 13th 2022

Results of our meta-analysis revealed that GLP-1 RA treatment decreases urinary albumin excretion and albumin to creatinine ratio but it did not cause significant changes in creatinine levels and glomerular filtration rate (British Journal of Clinical Pharmacology)

Categories: Medication, Nephropathy, News
Tags: creatinine, GFR, GLP-1 RA

Categories: Medication, Nephropathy
Tags: creatinine, GFR, GLP-1 RA

Exploratory study reveals far reaching systemic and cellular effects of verapamil treatment in subjects with type 1 diabetes

March 9th 2022

The current studies provide crucial mechanistic and clinical insight into the beneficial effects of verapamil in T1D (Nature)

Categories: Medication, News
Tags: Type 1 Diabetes, verapamil

Categories: Medication
Tags: Type 1 Diabetes, verapamil

Real-world Evidence of Efficacy and Safety of SGLT2 Inhibitors as Adjunctive Therapy in Adults With Type 1 Diabetes: A European Two-Center Experience

March 6th 2022

Our real-world data on SGLT2i showed promising results in reductions in HbA1c, weight, and insulin requirements in type 1 diabetes. Benefits were more pronounced in individuals with higher baseline HbA1c and BMI. DKA remained a major concern, despite educational measures (Diabetes Care)

Categories: Medication, News
Tags: SGLT2 inhibitors, Type 1 Diabetes

Categories: Medication
Tags: SGLT2 inhibitors, Type 1 Diabetes

Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial

March 1st 2022

The benefit was consistent in adults with new or existing heart failure and in those with either preserved or reduced ejection fraction (Boehringer Ingelheim)

Categories: Cardiovascular, Medication, News
Tags: Empagliflozin, EMPULSE

Categories: Cardiovascular, Medication
Tags: Empagliflozin, EMPULSE

Effectiveness and safety of teneligliptin added to patients with type 2 diabetes inadequately controlled by oral triple combination therapy: A multicentre, randomized, double-blind, and placebo-controlled study

March 1st 2022

The current study shows that teneligliptin could be a valid option as a fourth OAD for treatment of patients with T2D inadequately controlled with a triple combination of OADs (Diabetes, Obesity and Metabolism)

Categories: Medication, News
Tags: teneligliptin, Type 2 Diabetes

Categories: Medication
Tags: teneligliptin, Type 2 Diabetes

Glucagon-Like Peptide-1 Receptor Agonist Use in People Living with Type 2 Diabetes Mellitus and Chronic Kidney Disease: A Narrative Review of the Key Evidence with Practical Considerations

February 18th 2022

Here, we review evidence on GLP-1 RA use in people living with T2DM and CKD and summarize renal outcomes from clinical studies. We provide practical considerations for GLP-1 RA use to provide an added benefit to guide treatment in this high-risk patient population (Diabetes Therapy)

Categories: Medication, Nephropathy, News
Tags: CKD, GLP-1 RA, Type 2 Diabetes

Categories: Medication, Nephropathy
Tags: CKD, GLP-1 RA, Type 2 Diabetes

Impacts of Sodium/Glucose Cotransporter-2 Inhibitors on Circulating Uric Acid Concentrations: A Systematic Review and Meta-Analysis

February 17th 2022

SGLT2i can be a valid therapeutic strategy for patients with T2DM and comorbid hyperuricemia. Besides reducing FPG, body weight, and HbA1c, SGLT2i can significantly decrease SUA levels compared to placebo (Journal of Diabetes Research)

Categories: Medication, News
Tags: SGLT2 inhibitors, uric acid

Categories: Medication
Tags: SGLT2 inhibitors, uric acid

Cardiovascular and Renal Outcomes with Canagliflozin in Patients with Peripheral Artery Disease: Data from the CANVAS program and CREDENCE trials

February 16th 2022

Patients with T2D and PAD derived similar relative cardiorenal benefits from canagliflozin treatment but higher absolute benefits compared to those without PAD, with no increase in MALE (Diabetes, Obesity and Metabolism)

Categories: Cardiovascular, Medication, Nephropathy, News
Tags: canagliflozin

Categories: Cardiovascular, Medication, Nephropathy
Tags: canagliflozin
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 51
  • Next Page »

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Gold Sponsors

AstraZenecaNovo NordiskBoehringer IngelheimNapp Diabetes

Silver Sponsors

Welsh Endocrinology and Diabetes Society (WEDS)About Ascensia Diabetes CareAbbott Diabetes Care

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Categories

  • Audits
  • Bariatric
  • Biochemistry
  • Cardiovascular
  • Devices
  • Diagnosis
  • Diet
  • Education
  • Epidemiology
  • Genetics
  • Gestational
  • Guidance
  • Guidelines
  • Hepatology
  • Hypertension
  • Immunology
  • Management
  • Media
  • Medication
  • Meetings
  • Monitoring
  • Nephrology
  • Neuropathy
  • Nephropathy
  • Obesity
  • Ophthalmology
  • Paediatrics
  • Pathology
  • Pharma
  • Pharmacology
  • Physiology
  • Podiatry
  • Prediabetes
  • Prevalence
  • Prevention
  • Psychological
  • Reports
  • Research
  • Screening
  • Sponsorship
  • Technology
  • Testing
  • Transplantation
  • Treatment
  • Wound Care

To see all articles associated with a category just click on the category name.

Popular Tags

ADA BMI canagliflozin CGM CKD closed-loop COVID-19 dapagliflozin DPP4 DPP4 inhibitors Empagliflozin exenatide GLP-1 RA GLP-1RA GLP1 glycaemic control HbA1c heart failure hyperglycemia hypoglycemia incretin insulin insulin pump Insulin resistance Ketoacidosis liraglutide metformin microvascular mortality NAFLD NICE pioglitazone retinopathy semaglutide SGLT2 inhibitors sitagliptin statin sulfonylureas Type 1 Diabetes Type 2 Diabetes

To see all articles associated with a tag just click on the tag name.

Complete list of Tags ››

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2022 Glycosmedia Partnership